Table 2 HAE-specific medications used during study period (2006–2014) in 631 patients with HAE in the USa
HAE Medications | N (%) of Patients (N = 631) |
|---|---|
Icatibant and/or ecallantide only | 197 (31.2) |
Any use C1-INH(IV) | 434 (68.8) |
C1-INH(IV)/Cinrzye | 110 (17.4) |
C1-INH(IV)/Cinryze + icatibant/ecallantide | 97 (15.4) |
C1-INH(IV)/Berinert | 87 (13.8) |
C1-INH(IV)/Berinert + icatibant/ecallantide | 53 (8.4) |
C1-INH(IV)/Cinryze + C1-INH(IV)/Berinert + icatibant/ ecallantide | 49 (7.8) |
C1-INH(IV)/Cinryze + C1-INH(IV)/Berinert | 38 (6.0) |